微科研
连接会议、学者、机构、期刊的产学研服务平台
会议
会议目录
会议库
创建会议
会议投稿
联合办会
学者
学者目录
我的主页
机构
机构目录
创建机构
期刊
期刊目录
期刊入驻
期刊投稿
创办期刊
产学研
产学研资讯
发布供需
快速参会
创建会议
稿件处理
En
会议
学者
机构
期刊
产学研
快速参会
创建会议
稿件处理
科研
服务
Shukui Qin
科研成果
11
论文成果
代表作品
优先展示有引用数据的代表论文。
高引文章
按引用次数从高到低排列。
1
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
New England Journal of Medicine
2020
被引 7,505
2
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
The Lancet
2023
被引 741
3
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
The Lancet Oncology
2020
被引 642
4
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
The Lancet
2023
被引 525
5
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
Journal of Clinical Oncology
2021
被引 447
6
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
The Lancet Oncology
2021
被引 405
7
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
The Lancet Oncology
2021
被引 381
8
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study
2020
被引 197
9
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
2020
被引 196
10
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial
2022
被引 195
11
emerald-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.
2024
被引 161
最后更新： 2026/10/22 16:15:54
